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Background and Aims. Women with former gestational diabetes (fGDM) are characterized by impaired beta-cell function (BC).
Incretin hormones contribute to insulin secretion after oral administration of glucose. We aimed to assess the possible role of
incretins on altered insulin release in fGDM. Materials and Methods. We studied 104 fGDM women within 6 months after
delivery and 35 healthy women after normal pregnancy (CNT) with a 75g oral (OGTT) and a 0.33g/kg intravenous (IVGTT)
glucose test, both lasting 3h. The ratio of suprabasal areas under the concentration curves for glucose (dAUCGL) and C-peptide
(dAUCCP) evaluated BC during OGTT (BCOG) and IVGTT (BCIV). Incretin eﬀect was computed in all fGDM and in fGDM
with normal tolerance (fGDMNGT) and with impaired glucose regulation (fGDMIGR). Results.d A U C GL of fGDM was higher
(P<0.0001) than CNT for both tests; while dAUCCP were not diﬀerent. BCOG and BCIV were lower in fGDM versus CNT
(1.42 ± 0.17nmolCP/mmolGLUC versus 2.53 ± 0.61, P = 0.015 and 0.41 ± 0.03 versus 0.68 ± 0.10, P = 0.0006, respectively). IE
in CNT (66 ± 4%) was not diﬀerent from that of all fGDM (59 ± 3) and fGDMNGT (60 ± 3), but higher than that of fGDMIGR
(52 ± 6; P = 0.03). IE normalized to BMI was 2.77 ± 0.19% m2/kg in CNT, higher than that of fGDMIGR (1.75 ± 0.21; P = 0.02)
a n da l s oo ff G D M NGT (2.33 ± 0.11; P = 0.038). Conclusion. Compromised IE characterizes fGDMIGR. In both fGDM categories,
regardless their glucose tolerance, IE normalized to BMI was reduced, signifying an intrinsic characteristic of fGDM. Therefore,
the diminished IE of fGDM seems to reﬂect an early abnormality of the general beta-cell dysfunction in the progression toward
type 2 diabetes.
1.Introduction
The incretin eﬀect is the potentiation of the glucose-me-
diated insulin secretion due to the gut hormones, namely,
glucose-dependent insulinotropic polypeptide (GIP) and
glucagon-like peptide-1 (GLP-1). They are released by the
intestine in the blood stream after oral glucose load, such
as during an oral glucose tolerance test or a meal [1].
The incretin eﬀect has been demonstrated by comparing
insulin concentration during oral and intravenous glucose
administration that yielded the same peripheral glucose con-
centration; however, insulin concentration was signiﬁcantly
higher after the oral load. Since this happened despite the
same glucose levels than with the intravenous load [2],
the diﬀerence in insulin concentration was ascribed to the
eﬀect of the incretin hormones. In type 2 diabetic patients,
a reduction of this eﬀect has been reported [3, 4]a n d
pharmacological agents have been developed to restore this
eﬀect,importantformaintainingagoodglucosehomeostasis
[5].
Women with formergestational diabetes (fGDM)exhibit
markedly increased risk for the later development of type
2 diabetes and related complications. They often present
metabolic abnormalities in insulin sensitivity compared to
control subjects, but even greater diﬀerences have been ob-
served for beta-cell function. In a previous study on fGDM,
we have assessed beta-cell function by the analysis of two
independent tests, intravenous (IVGTT) and oral (OGTT)
glucose tolerance tests and found that the impairment in
beta-cell function was observable only with OGTT [6]. We
hypothesize that the incretin eﬀect may play a pivotal role2 International Journal of Endocrinology
in the subtle derangement of beta-cell function observed in
fGDM.
Therefore, the aim of this study was to evaluate the
incretin eﬀect in a larger group of fGDM, who underwent
both IVGTT and OGTT immediately after partum. They
were also divided according to their glucose tolerance to
evaluate if it plays some role on the possible changes of the
incretin eﬀect in fGDM.
2.MaterialsandMethods
A total of 104 fGDM were studied within 6 months after
delivery and compared to 35 healthy women after normal
pregnancy (CNT). Table 1 shows the main characteristics
of the two groups; body mass index (BMI) of fGDM was
borderline higher, but in general still in the overweight
range. Every subject randomly underwent a 75g OGTT
with sampling at 10, 20, 30, 60, 90, 120, 150, 180min
and a 0.33g/kg frequently sampled intravenous glucose test
(IVGTT) with insulin (0.03IU/kg, Humulin R; Eli Lilly,
Indianapolis, IN, USA) intravenous infusion at time 20
for 5min. Less than 3 weeks elapsed between the two
tests, without any diet or habit changes in between. Both
tests lasted 3h; glucose and C-peptide were determined in
duplicate by commercially available radioimmunoassay kits
with an interassay coeﬃcient of variation <5%. Further
details on the performance of the two tests were reported
previously [7, 8].
Out of 104 fGDM, 77 resulted with normal glucose
tolerance (fGDMNGT) according to the OGTT criteria of
the American Diabetes Association, 6 with type 2 diabetes
and 21 with impaired glucose regulation (fGDMIGR), which
included both impaired fasting glucose and impaired glucose
tolerance. All CNT exhibited normal glucose tolerance.
For the purpose of this study, we calculated the area
under the concentration curves (AUC) for glucose (AUCGL)
and C-peptide (AUCCP) for 3h in both tests, by using the
trapezoidal rule. The suprabasal, dynamic AUC (dAUC)
were computed by subtracting from the AUC the basal
area (i.e., fasting value × 180min). AUCCP represents the
absolute insulin release at the beta-cell level. The beta-cell
function describes the ability of glucose to stimulate insulin
release from the beta-cell. Beta-cell function during OGTT
(BCOG) and that during IVGTT (BCIV) were calculated
according to the respective ratio dAUCCP/dAUCGL in both
tests: units nmolCP/mmolGLUC. The incretin action occurs
only during an oral administration of glucose; thus, it can
be estimated by subtracting the glucose stimulated secretion
during the IVGTT from that evaluated during the OGTT:
the formula 100 ×(BCOG −BCIV)/BCOG yields therefore the
percent incretin eﬀect [3]. This approach has been already
successfully exploited in previous studies [9, 10].
In order to evaluate whether diﬀerent glucose tolerance
within the fGDM plays a role in the assessment of beta-
cell function and incretin eﬀect, these parameters were also
computed in the single subgroups of normotolerant and
impaired metabolism.
Data are expressed as mean ± SE; means have been com-
pared with the Student’s t-test.
3. Results
Fasting and total AUC glucose in both tests were markedly
higher in fGDM (Table 1); fasting C-peptide was not dif-
ferent, while the dynamic C-peptide response to glucose
stimulation only tended to be higher in fGDM, but only
with borderline signiﬁcance. Suprabasal AUC of glucose
(dAUCGL), which represents the main stimulus to the
secretory response of the beta-cell, was higher in fGDM than
that of CNT for both tests (338 ± 20mmol/L 3h versus
189 ± 21, P = 0.0001 for OGTT; 206 ± 13 versus 119 ±
16, P = 0.0002 for IVGTT). Dynamic insulin secretion,
dAUCCP was not diﬀerent between fGDM and CNT in both
tests, but much higher (P<0.00001) during OGTT (285 ±
9nmol/L 3h versus 257 ± 15, P = 0.13 fGDM versus CNT
for OGTT; 61 ± 3v e r s u s5 5± 5, P = 0.36 for IVGTT).
Beta-cell function and incretin eﬀect are shown in
Table 2, where fGDM was also divided into fGDMNGT and
fGDMIGR, the latter presenting with higher BMI. From these
subgroups the 6 type 2 diabetics were excluded, since their
small number allowed no statistical power for any possible
comparison. BCOG was markedly higher than BCIV in both
fGDM and CNT (P = 0.003); both BCOG and BCIV were
lower in fGDM (all together) compared to CNT; and were
lower in fGDMIGR compared to fGDMNGT.
When comparing the normotolerant fGDMNGT to CNT,
both BCOG and BCIV were not diﬀerent, while beta-cell
functions of fGDMIGR were signiﬁcantly lower than those
of CNT. Incretin eﬀect resulted similar between fGDM all
together and CNT; that of fGDMNGT was not diﬀerent from
that of CNT (P value ranging in both cases 0.2–0.8); while
that of fGDMIGR was signiﬁcantly lower than that of women
with normal pregnancy (Table 2). When incretin eﬀect was
normalized to BMI, to take into account that the main
determinant of IGR was the increased BMI, the diﬀerences
in the incretin eﬀect were even more substantial. The value
for CNT was 2.77 ± 0.19%m2/kg, still higher than that of
fGDMIGR (1.75 ± 0.21; P = 0.019), but also the diﬀerence
with that of fGDMNGT (2.33±0.11) became signiﬁcant (P =
0.038). Incretin eﬀect normalized to BMI was 2.21 ± 0.10;
P = 0.006 versus CNT).
4. Discussion
Within a short period after partum, beta-cell function, eval-
uated both with the oral and with the intravenous glucose
tests, was reduced in a general population of overweight
women who exhibited gestational diabetes mellitus during
pregnancy [7]. Indeed, in both tests, fGDM exhibited C-
peptide release only slightly increased despite markedly
higher glucose. Results of this study show that incretins do
not play a fundamental role in this observed reduced beta-
cell function characterizing fGDM: in fact, the surrogate
index of incretin eﬀect used here did not diﬀer from the
same index evaluated in a population of healthy women,
who had a normal pregnancy, studied within the same
period after partum. In both CNT and fGDM, the beta-cell
functionobtainedwiththeOGTTwasmuchhigherthanthat
with IVGTT, showing that incretins have a potent eﬀect inInternational Journal of Endocrinology 3
Table 1: Main characteristics and area under the concentration curve (AUC) of glucose and C-peptide, in the two tests, for women with
former gestational diabetes (fGDM) and women who had normal pregnancy (CNT).
fGDM CNT P value
N 104 35
Age (time of the study) (years) 33.5 ±0.53 1 .8 ±0.9 0.076
Body mass index (kg/m2)2 7 .3 ±0.52 5 .3 ±1.0 0.048
Fasting glucose (mmol/L) 5.08 ±0.08 4.62 ±0.06 0.0008
Fasting insulin (pmol/L) 60 ±45 7 ±5 0.668
Fasting C-peptide (pmol/L) 646 ±31 582 ±31 0.258
AUC glucose (OGTT) (mol/L 3h) 1.26 ±0.03 1.02 ±0.02 0.00001
AUC C-peptide (OGTT) (nmol/L 3h) 402 ±13 353 ±19 0.048
AUC glucose (IVGTT) (mol/L 3h) 0.98 ±0.02 0.85 ±0.02 0.0001
AUC C-peptide (IVGTT) (nmol/L 3h) 150 ±8 122 ± 9 0.055
Table 2: Beta-cell function from OGTT (BCOG)a n dI V G T T( B C IV) and incretin eﬀect (IE) in all fGDM and in the two subgroups of fGDM
characterized by normal glucose tolerance (fGDMNGT) and impaired glucose metabolism (fGDMIGR), compared to women who had normal
pregnancy (CNT).
fGDMIGR fGDMNGT Pa CNT Pb all fGDM Pc
N 21 77 35 104
BMI 30.2 ±1.02 6 .2 ±0.5 0.001 27.3 ±0.5 0.001 25.3 ±1.0 0.048
BCOG 0.67 ±0.06 1.70 ±0.21 0.014 2.53 ±0.61 0.023 1.42 ±0.17 0.016
BCIV 0.29 ±0.17 0.47 ±0.04 0.011 0.61 ±0.10 0.020 0.41 ±0.03 0.012
IE 51.5 ±5.86 0 .0 ±2.8 0.171 65.8 ±3.6 0.030 58.9 ±2.5 0.146
BMI: body mass index (kg/m2); units for BCOG and BCIV:n m o l CP/mmolGLUC; for IE: %; all fGDM include also 6 fGDM type 2 diabetic women; P values:
afGDMIGR versus fGDMNGT; bfGDMIGR versus CNT; call fGDM versus CNT.
both groups. The elevated beta-cell response during OGTT
could mask possible signiﬁcant diﬀerences in the beta-cell
sensitivity to glucose between fGDM and CNT; however, no
diﬀerence is also highlighted by the IVGTT, which provides
the evaluation independent on incretins.
Our results on beta-cell function seem to be in contrast
withapreviousstudy[11],whereitisreportedanunchanged
beta-cell function in fGDM. However, in that study, the
authors used the 30 min insulinogenic index with insulin,
which is known to be not fully reliable [12], while the
present investigation exploited C-peptide evaluated during
the whole 3h duration of the test: a more reliable ﬁgure
of the incretin-mediated sensitivity of the beta-cell to the
glucose stimulation. To quantify this process, we have used
the percent (normalized) diﬀerence of the beta-cell function
between the tests, which gauges the relative contribution of
the incretins in fostering glucose-dependent insulin release.
We have used the beta-cell function instead of the simple
AUCs as previously done [3, 9, 10], because the OGTT and
the IVGTT did not yield isoglycemic patterns; thus, we had
to normalize the insulin release to glucose with the ratios
dAUCCP/dAUCGL. The incretin eﬀect we estimated is a kind
of general measurement and cannot discriminate between
the real eﬀect of the incretins and the possible reduction
in fGDM of the incretins production [13]. In fact, our
measurement is an indirect surrogate, since we have not
measured the incretin hormones concentration. This is the
main weakness of our study. Having for instance the pattern
of GLP-1, we could apply another straightforward method
[14] that quantiﬁes the direct incretin action, independently
on the actual hormone secretion. Some investigators found
a mildly reduced GLP-1 response to oral glucose only during
theﬁrst30min,whiletheentire2hGLP-1AUCdidnotdiﬀer
from that of the control subjects [13]. This was substantiated
by other studies that reported no diﬀerences in the secretion
of incretin hormones after oral glucose ingestion in women
with a history of gestational diabetes [11]. Therefore, we
are quite conﬁdent that the incretin eﬀect we observed in
our study is prevalently due to the action of incretins in
sensitizing the beta-cell.
Ar e c e n tr e p o r t[ 10] showed that incretin eﬀect is
reduced with obesity, which is known to be characterized
by insulin resistance and reduced glucose tolerance. Another
study related incretin eﬀect to various degrees of glucose
intolerance [15]. These ﬁndings in a general population were
then veriﬁed in our fGDM, who were divided into normo-
and impaired tolerant. To the best of our knowledge, this is a
novelty of our study. We have found a clear reduction in the
incretin eﬀect in fGDM with IGR. Incretin eﬀect was instead
similar between former GDM with NGT and CNT. The
reasonmaybeinthefactthatIGRhaveaslightlyhigherBMI,
though not reaching overt obesity yet. This fact corroborates
moreourpoint,sinceitisknownthatobesityisaccompanied
by hyperinsulinemia before the onset of overt diabetes. Thus
the circumstance that fGDMIGR still presents reduced beta-
cell sensitivity to glucose, despite higher BMI, appears to4 International Journal of Endocrinology
be an intrinsic defect of this population. In fact, when the
incretin eﬀect was normalized to BMI, fGDMNGT too had
a lower index, despite similar BMI than CNT. Since the
majority of fGDM return normal after delivery, in general,
we can claim that a reduced incretin eﬀect likely remains a
characteristic of this condition.
In conclusion, normotolerant women with previous ges-
tational diabetes exhibit an incretin eﬀect similar to that of
healthywomen,whohadanormalpregnancy.Compromised
incretin eﬀect, proper of obese and type 2 diabetic subjects,
characterizesinsteadfGDMwithimpairedglucosetolerance,
probably related to their, though slightly, augmented body
weight. When the incretin eﬀect was evaluated after nor-
malization to BMI, it resulted in reduced in both categories,
giving the impression of an intrinsic characteristic of fGDM,
regardlessoftheirglucosetolerance.Thediminishedincretin
eﬀect of fGDM seems therefore to reﬂect an early abnormal-
ity of the general beta-cell dysfunction in the progression
toward type 2 diabetes.
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